Tag: pharmaceuticals
-
Revive’s (RVV.C) Bucillamine Covid-19 treatment advances through development pipeline
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions.
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
I asked Twitter what tickers I should be writing about: Twitter had 35 ideas… here’s 6 of them
Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three…
-
Biotech: Who Will Survive When The COVID-19 Hype Ends?
Over the last couple of months, companies have found a way to muster up an effort to align their objectives with helping society recover from this global pandemic – COVID-19. The result: share prices have soared like never before. The line up of biotech companies trying to come up with COVID-19 vaccines or cures is…
-
Revive Therapeutics’ (RVV.C) product pipeline is flowing freakishly fast
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
-
Revive Therapeutics (RVV.C): Kicked around, called a fraud, gets FDA approval of Phase 3 COVID-19 trials
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he put out news claiming his little pharma company, which had built a reputation for chasing aggressively into new pharmaceutical fields, had found some IP that might be useful in the…
-
Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts…
